Nabriva Therapeutics AG (NBRV) Stock
NBRV is no longer traded. Nabriva Therapeutics AG was delisted from the Nasdaq in October 2023.
Prices on this page are historical; the last trade was October 2, 2023 at $0.40.
Nabriva Therapeutics AG stock price history
NBRV final trading statistics
- Final close
- $0.40
- Final trading day
- Oct 2, 2023
- Market cap at delisting
- $4.55M
- Shares outstanding
- 3.20M
- Final 52-week range
- $0.37 – $2.87
- Avg. volume (final 3 mo.)
- 20,579
- All-time high (split-adj.)
- $82750.00 · Sep 2015
- All-time low (split-adj.)
- $0.40 · Oct 2023
- Return since IPO
- -100.0%
- Beta
- 1.55
- Book value / share
- -$1.36
- Price / book
- -0.29
Nabriva Therapeutics AG annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $35.67M | -$57.2M | -$17.86 |
| FY2021 | $27.22M | -$49.5M | -$27.02 |
| FY2020 | $2.86M | -$69.5M | -$147.75 |
| FY2019 | $7.75M | -$82.8M | -$280.00 |
| FY2018 | $6.50M | -$114.8M | -$392.50 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics AG stock FAQ
What happened to Nabriva Therapeutics AG stock?
Nabriva Therapeutics AG stock was delisted from the Nasdaq. Its final close was $0.40 on October 2, 2023.
Is NBRV stock still trading?
No. NBRV was delisted from the Nasdaq in October 2023 and no longer trades on a U.S. exchange.
What was the last price of NBRV stock?
NBRV closed at $0.40 on its final trading day, October 2, 2023, for a market value of about $4.55M.
What were Nabriva Therapeutics AG's revenue and earnings in its last full fiscal year?
Nabriva Therapeutics AG reported revenue of $35.67M and net income of -$57.2M in fiscal 2022, its last full year as a public company.
When did Nabriva Therapeutics AG go public?
Nabriva Therapeutics AG stock began trading on September 18, 2015.